Anaplastic thyroid cancer: outcome and the mutation/expression profiles of potential targets

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Anaplastic thyroid cancer (ATC) is a rare, aggressive thyroid malignancy with limited treatment options.
• Targeted therapies, particularly protein kinase inhibitors, show promise in preclinical studies for ATC.
• Identifying actionable mutations and biomarkers is crucial for developing effective treatments.

Purpose of the Study:

• To investigate the mutational status of key therapeutic targets (BRAF, KRAS, EGFR) in ATC.
• To assess the expression of C-KIT and PDL1 as potential biomarkers for targeted therapy and immunotherapy.
• To correlate biomarker status with clinical outcomes in ATC patients.

Main Methods:

• Analysis of BRAF, KRAS, and EGFR mutations using allele-specific PCR and Sanger sequencing.
• Assessment of C-KIT and PDL1 protein expression via immunohistochemistry.
• Correlation of molecular findings with clinical data and patient survival.

Main Results:

• BRAF V600E mutation was present in 23% (3/13) of ATC patients.
• C-KIT overexpression was observed in 8% (1/13) of patients, who responded to a tyrosine kinase inhibitor.
• PDL1 expression was detected in 23% (3/13) of patients, none of whom were surgical candidates.
• KRAS and EGFR mutations were absent in all analyzed specimens.

Conclusions:

• Targeted therapies, including protein kinase inhibitors, may offer therapeutic benefits for ATC.
• Immunotherapy targeting PDL1 could be a potential strategy for a subset of ATC patients.
• BRAF V600E mutation and C-KIT overexpression are relevant biomarkers for guiding treatment decisions in ATC.